Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 11;10(1):e003289. doi: 10.1136/jitc-2021-003289

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Modeling of CD70s influence on GBM TIME. (A) CD70 expression kinetics on in-house, activated T cells and (B) levels of CD69 and cMyc displayed by CD70CAR or ConCAR-T cells 9 days post-transduction, evaluated by flow cytometry. (C) CD70-enriched or -silenced Jurkat cells were transduced with either ConCAR or CD70CAR. After 8 days, CD69 and CD70 levels were assessed by flow cytometry. (D) TIME cells extracted from patient tumor samples were analyzed by flow cytometry, evaluating the pattern of expression of CD27 in non-lymphoid (CD45+CD3-) and M1 populations (CD45+CD3-CD68+HLADR+). (E) Average expression of CD27 on CD4/CD8 lymphoid population, and CD70 expression on the lymphoid population (CD3+). CAR, chimeric antigen receptor; GBM, glioblastoma; TIME, tumor immune microenvironment.